BVS
Bioventus Inc.
Price Chart
Latest Quote
$8.71
+0.17 (+1.99%)
Current Price
| Previous Close | $8.54 |
| Open | $8.61 |
| Day High | $8.86 |
| Day Low | $8.61 |
| Volume | 804,396 |
Stock Information
| Shares Outstanding | 67.75M |
| Total Debt | $288.42M |
| Cash Equivalents | $35.85M |
| Revenue | $576.30M |
| Net Income | $28.48M |
| Sector | Healthcare |
| Industry | Medical Devices |
| Market Cap | $590.09M |
| P/E Ratio | 21.24 |
| EPS (TTM) | $0.41 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $888.70M |
| Sales | $576.30M |
| Income | $28.48M |
| Book/sh | $2.79 |
| Cash/sh | $0.53 |
| Employees | 940 |
Financial Ratios
| Quick Ratio | 1.06 |
| Current Ratio | 1.69 |
| Debt/Eq | 123.12 |
Returns & Margins
| ROA | 5.61% |
| ROE | 16.46% |
| Gross Margin | 68.69% |
| Operating Margin | 6.73% |
| Profit Margin | 4.94% |
Ownership
| Insider Ownership | 11.75% |
| Institutional Ownership | 78.28% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | 9.61 |
| PEG | 1.13 |
| P/S | 1.02 |
| P/B | 3.12 |
Analyst Data
| Recommendation | none |
| Target Price | $14.80 |
Technical Indicators
| SMA20 | $8.77 |
| SMA50 | $9.61 |
| SMA200 | $8.19 |
| RSI | 53.05 |
| ATR | 0.3909 |
| Shares Float | 33.29M |
| Short Float | 3.97% |
| Short Ratio | 3.04 |
| Volatility | 0.67 |
| Rel Volume | 1.41 |
Performance History
| Week | +0.35% |
| Month | -18.29% |
| Quarter | -3.22% |
| 6 Months | +15.82% |
| YTD | +20.80% |
| Year | +37.17% |
| 3 Years | +181.88% |
| 5 Years | -52.71% |
| 10 Years | -54.66% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $8.71 | 1,060,200 |
| 2026-06-17 | $8.54 | 366,800 |
| 2026-06-16 | $8.72 | 370,700 |
| 2026-06-15 | $8.60 | 631,900 |
| 2026-06-12 | $8.51 | 463,200 |
| 2026-06-11 | $8.68 | 593,500 |
| 2026-06-10 | $9.05 | 400,700 |
| 2026-06-09 | $9.20 | 488,900 |
| 2026-06-08 | $8.95 | 485,200 |
| 2026-06-05 | $9.04 | 698,400 |
| 2026-06-04 | $8.70 | 836,200 |
| 2026-06-03 | $8.55 | 1,364,200 |
| 2026-06-02 | $8.11 | 1,128,300 |
| 2026-06-01 | $7.93 | 866,700 |
| 2026-05-29 | $8.51 | 711,400 |
| 2026-05-28 | $8.87 | 506,100 |
| 2026-05-27 | $8.90 | 1,057,200 |
| 2026-05-26 | $9.02 | 781,400 |
| 2026-05-22 | $9.28 | 734,900 |
| 2026-05-21 | $9.49 | 1,516,200 |
| 2026-05-20 | $10.94 | 389,200 |
| 2026-05-19 | $10.66 | 475,800 |
About Bioventus Inc.
Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company's product portfolio includes pain treatments, which comprise various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain, and TalisMann provides stimulation to the targeted peripheral nerve, as well as XCELL PRP System, a benchtop device that processes whole blood to produce high-yield PRP with a 10-minute single-spin cycle. It also offers precision bone resection for patients with degenerative spine conditions and spinal deformities, as well as enables precision ultrasonic neuro and general surgery to address brain tumors and pathologies of the liver and other organs; and bone graft substitutes, including various products that facilitate optimal bone fusion. In addition, the company provides neXus, an ultrasonic surgical system; BoneScalpel, a surgical solution enabling precise cuts in hard tissue; BoneScalpel Access, for bone removal with visualization; SonaStar system, a precise ablation and removal of soft tissue; SonaStar Elite handpiece and accessories; SonicOne, an ultrasonic cleansing and debridement system; Osteoamp, an allograft-derived bone graft for orthopedic, neurosurgical, and reconstructive bone grafting procedures; Signafuse bone graft; Purebone, a natural osteoconductive scaffold; and Reficio demineralized bone matrix. The company's restorative therapies include minimally invasive fracture treatments and rehabilitation products. Its products also include Exogen, an ultrasound bone stimulation system. The company sells its products to healthcare institutions, physicians, patients, distributors and dealers. Bioventus Inc. was founded in 2011 and is headquartered in Durham, North Carolina.
đ° Latest News
Are Investors Undervaluing Bioventus (BVS) Right Now?
Zacks âĸ 2026-06-09T13:40:03Z
Bioventus Highlights PNS, PRP Growth as Cash Flow Improves and Debt Falls
MarketBeat âĸ 2026-06-08T23:03:20Z
Are Medical Stocks Lagging Allarity Therapeutics, Inc. (ALLR) This Year?
Zacks âĸ 2026-06-03T13:40:06Z
After Plunging 22% in 4 Weeks, Here's Why the Trend Might Reverse for Bioventus (BVS)
Zacks âĸ 2026-06-02T13:35:02Z
Bioventus (BVS) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Zacks âĸ 2026-05-29T13:55:02Z
Is Bioventus (BVS) Stock Undervalued Right Now?
Zacks âĸ 2026-05-21T13:40:03Z
Are Medical Stocks Lagging Bioventus (BVS) This Year?
Zacks âĸ 2026-05-18T13:40:03Z
Consumer Sentiment Just Crashed Below the Recession Threshold. These 3 Defensive Stocks Under $25 Are Built for What Comes Next
24/7 Wall St. âĸ 2026-05-14T15:47:14Z
Bioventus' (NASDAQ:BVS) Solid Earnings Are Supported By Other Strong Factors
Simply Wall St. âĸ 2026-05-14T12:12:33Z
Wall Street Analysts See a 38.97% Upside in Bioventus (BVS): Can the Stock Really Move This High?
Zacks âĸ 2026-05-08T13:55:04Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $138,646,000 | $143,151,000 | $135,629,000 | $135,387,000 |
| Cost Of Revenue | $179,930,000 | $185,054,000 | $184,152,000 | $181,037,000 |
| Total Revenue | $568,087,000 | $573,280,000 | $512,345,000 | $512,117,000 |
| Operating Revenue | $568,087,000 | $573,280,000 | $512,345,000 | $512,117,000 |
| Expenses | ||||
| Interest Expense | $26,486,000 | $38,792,000 | $40,676,000 | $12,021,000 |
| Total Expenses | $511,796,000 | $550,455,000 | $510,319,000 | $546,773,000 |
| Other Income Expense | $-4,096,000 | $-36,375,000 | $-82,461,000 | $-142,348,000 |
| Other Non Operating Income Expenses | $-1,454,000 | $1,645,000 | $1,290,000 | $-9,770,000 |
| Net Non Operating Interest Income Expense | $-26,486,000 | $-38,792,000 | $-40,676,000 | $-12,021,000 |
| Interest Expense Non Operating | $26,486,000 | $38,792,000 | $40,676,000 | $12,021,000 |
| Operating Expense | $331,866,000 | $365,401,000 | $326,167,000 | $365,736,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $22,732,000 | $-36,125,000 | $-81,801,000 | $-89,964,000 |
| Net Interest Income | $-26,486,000 | $-38,792,000 | $-40,676,000 | $-12,021,000 |
| Normalized Income | $24,819,180 | $-1,945,020 | $-15,637,710 | $11,458,170 |
| Net Income From Continuing And Discontinued Operation | $22,732,000 | $-36,125,000 | $-156,230,000 | $-158,704,000 |
| Total Operating Income As Reported | $53,975,000 | $-15,195,000 | $-81,725,000 | $-167,234,000 |
| Net Income Common Stockholders | $22,732,000 | $-36,125,000 | $-156,230,000 | $-158,704,000 |
| Net Income | $22,732,000 | $-36,125,000 | $-156,230,000 | $-158,704,000 |
| Net Income Including Noncontrolling Interests | $27,274,000 | $-47,049,000 | $-195,625,000 | $-213,391,000 |
| Net Income Discontinuous Operations | $0 | $0 | $-74,429,000 | $-68,740,000 |
| Net Income Continuous Operations | $27,274,000 | $-47,049,000 | $-121,196,000 | $-144,651,000 |
| Pretax Income | $25,709,000 | $-52,342,000 | $-121,111,000 | $-189,025,000 |
| Special Income Charges | $-2,642,000 | $-38,020,000 | $-83,751,000 | $-132,578,000 |
| Operating Income | $56,291,000 | $22,825,000 | $2,026,000 | $-34,656,000 |
| Depreciation Amortization Depletion Income Statement | $5,727,000 | $7,652,000 | $8,842,000 | $9,748,000 |
| Depreciation And Amortization In Income Statement | $5,727,000 | $7,652,000 | $8,842,000 | $9,748,000 |
| Gross Profit | $388,157,000 | $388,226,000 | $328,193,000 | $331,080,000 |
| Per Share | ||||
| Diluted EPS | $0.33 | $-0.52 | $-2.49 | $-2.59 |
| Basic EPS | $0.34 | $-0.52 | $-2.49 | $-2.59 |
| Other | ||||
| Tax Effect Of Unusual Items | $-554,820 | $-3,840,020 | $-17,587,710 | $-31,155,830 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $101,848,000 | $74,025,000 | $60,681,000 | $10,972,000 |
| Total Unusual Items | $-2,642,000 | $-38,020,000 | $-83,751,000 | $-132,578,000 |
| Total Unusual Items Excluding Goodwill | $-2,642,000 | $-38,020,000 | $-83,751,000 | $-132,578,000 |
| Reconciled Depreciation | $47,011,000 | $49,555,000 | $57,365,000 | $55,398,000 |
| EBITDA (Bullshit earnings) | $99,206,000 | $36,005,000 | $-23,070,000 | $-121,606,000 |
| EBIT | $52,195,000 | $-13,550,000 | $-80,435,000 | $-177,004,000 |
| Diluted Average Shares | $68,914,895 | $64,547,474 | $62,647,554 | $61,389,107 |
| Basic Average Shares | $66,622,631 | $64,547,474 | $62,647,554 | $61,389,107 |
| Diluted NI Availto Com Stockholders | $22,732,000 | $-36,125,000 | $-156,230,000 | $-158,704,000 |
| Minority Interests | $-4,542,000 | $10,924,000 | $39,395,000 | $54,687,000 |
| Tax Provision | $-1,565,000 | $-5,293,000 | $85,000 | $-44,374,000 |
| Gain On Sale Of Ppe | $-81,000 | $-292,000 | $-3,577,000 | $0 |
| Other Special Charges | $326,000 | - | - | - |
| Impairment Of Capital Assets | $0 | $36,357,000 | $78,615,000 | $124,697,000 |
| Restructuring And Mergern Acquisition | $2,235,000 | $1,371,000 | $1,559,000 | $7,881,000 |
| Research And Development | $12,113,000 | $13,951,000 | $13,446,000 | $23,854,000 |
| Selling General And Administration | $314,026,000 | $343,798,000 | $303,879,000 | $332,134,000 |
| Write Off | - | - | $0 | $0 |
Fetched: 2026-06-17
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-191,776,000 | $-264,251,000 | $-316,221,000 | $-322,075,000 |
| Total Assets | $683,559,000 | $727,956,000 | $810,910,000 | $1,372,649,000 |
| Total Non Current Assets | $410,717,000 | $452,346,000 | $542,911,000 | $1,100,074,000 |
| Other Non Current Assets | $2,293,000 | $1,892,000 | $3,141,000 | $408,615,000 |
| Non Current Deferred Assets | $5,522,000 | $4,745,000 | $0 | $0 |
| Non Current Deferred Taxes Assets | $5,522,000 | $4,745,000 | $0 | $0 |
| Goodwill And Other Intangible Assets | $375,881,000 | $412,191,000 | $489,812,000 | $647,313,000 |
| Other Intangible Assets | $368,419,000 | $404,729,000 | $482,350,000 | $639,851,000 |
| Current Assets | $272,842,000 | $275,610,000 | $267,999,000 | $272,575,000 |
| Other Current Assets | $11,065,000 | $14,160,000 | $16,913,000 | $18,551,000 |
| Inventory | $82,236,000 | $92,475,000 | $91,333,000 | $84,766,000 |
| Receivables | $128,303,000 | $127,393,000 | $122,789,000 | $136,295,000 |
| Accounts Receivable | $128,303,000 | $127,393,000 | $122,789,000 | $136,295,000 |
| Allowance For Doubtful Accounts Receivable | $-2,903,000 | $-2,864,000 | $-4,219,000 | $-7,022,000 |
| Gross Accounts Receivable | $131,206,000 | $130,257,000 | $127,008,000 | $143,317,000 |
| Cash Cash Equivalents And Short Term Investments | $51,238,000 | $41,582,000 | $36,964,000 | $30,186,000 |
| Cash And Cash Equivalents | $51,238,000 | $41,582,000 | $36,964,000 | $30,186,000 |
| Assets Held For Sale Current | - | - | $0 | $2,777,000 |
| Restricted Cash | - | - | - | $23,000 |
| Prepaid Assets | - | - | - | $4,442,000 |
| Debt | ||||
| Net Debt | $242,713,000 | $294,045,000 | $357,882,000 | $387,880,000 |
| Total Debt | $293,951,000 | $335,627,000 | $394,846,000 | $418,066,000 |
| Long Term Debt And Capital Lease Obligation | $278,951,000 | $308,288,000 | $366,998,000 | $385,010,000 |
| Long Term Debt | $278,951,000 | $308,288,000 | $366,998,000 | $385,010,000 |
| Current Debt And Capital Lease Obligation | $15,000,000 | $27,339,000 | $27,848,000 | $33,056,000 |
| Current Debt | $15,000,000 | $27,339,000 | $27,848,000 | $33,056,000 |
| Other Current Borrowings | $15,000,000 | $27,339,000 | $27,848,000 | $33,056,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $455,112,000 | $542,352,000 | $589,792,000 | $960,427,000 |
| Total Non Current Liabilities Net Minority Interest | $294,732,000 | $331,954,000 | $414,295,000 | $656,410,000 |
| Other Non Current Liabilities | $15,348,000 | $23,102,000 | $46,084,000 | $40,241,000 |
| Non Current Deferred Liabilities | $433,000 | $564,000 | $1,213,000 | $2,248,000 |
| Non Current Deferred Taxes Liabilities | $433,000 | $564,000 | $1,213,000 | $2,248,000 |
| Current Liabilities | $160,380,000 | $210,398,000 | $175,497,000 | $304,017,000 |
| Other Current Liabilities | $21,062,000 | $43,527,000 | $24,518,000 | $139,641,000 |
| Payables And Accrued Expenses | $117,758,000 | $131,934,000 | $113,422,000 | $119,892,000 |
| Interest Payable | $3,168,000 | $5,324,000 | $6,606,000 | $217,000 |
| Payables | $16,063,000 | $27,558,000 | $27,787,000 | $39,269,000 |
| Total Tax Payable | $5,135,000 | $3,868,000 | $4,749,000 | $2,572,000 |
| Accounts Payable | $10,928,000 | $23,690,000 | $23,038,000 | $36,697,000 |
| Liabilities Heldfor Sale Non Current | - | - | $0 | $228,911,000 |
| Current Deferred Liabilities | - | - | - | $117,615,000 |
| Equity | ||||
| Common Stock Equity | $184,105,000 | $147,940,000 | $173,591,000 | $325,238,000 |
| Total Equity Gross Minority Interest | $228,447,000 | $185,604,000 | $221,118,000 | $412,222,000 |
| Stockholders Equity | $184,105,000 | $147,940,000 | $173,591,000 | $325,238,000 |
| Gains Losses Not Affecting Retained Earnings | $-1,900,000 | $-2,573,000 | $794,000 | $-110,000 |
| Other Equity Adjustments | $-1,900,000 | $-2,573,000 | $794,000 | $-110,000 |
| Retained Earnings | $-334,929,000 | $-357,661,000 | $-321,536,000 | $-165,306,000 |
| Other | ||||
| Ordinary Shares Number | $67,097,716 | $65,758,341 | $63,267,436 | $62,063,014 |
| Share Issued | $67,097,716 | $65,758,341 | $63,267,436 | $62,063,014 |
| Tangible Book Value | $-191,776,000 | $-264,251,000 | $-316,221,000 | $-322,075,000 |
| Invested Capital | $478,056,000 | $483,567,000 | $568,437,000 | $743,304,000 |
| Working Capital | $112,462,000 | $65,212,000 | $92,502,000 | $-31,442,000 |
| Total Capitalization | $463,056,000 | $456,228,000 | $540,589,000 | $710,248,000 |
| Minority Interest | $44,342,000 | $37,664,000 | $47,527,000 | $86,984,000 |
| Additional Paid In Capital | $520,851,000 | $508,092,000 | $494,254,000 | $490,576,000 |
| Capital Stock | $83,000 | $82,000 | $79,000 | $78,000 |
| Common Stock | $83,000 | $82,000 | $79,000 | $78,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $6,560,000 | $7,598,000 | $9,709,000 | $11,428,000 |
| Current Accrued Expenses | $101,695,000 | $104,376,000 | $85,635,000 | $80,623,000 |
| Goodwill | $7,462,000 | $7,462,000 | $7,462,000 | $7,462,000 |
| Net PPE | $27,021,000 | $33,518,000 | $49,958,000 | $44,146,000 |
| Accumulated Depreciation | $-54,264,000 | $-50,186,000 | $-40,504,000 | $-30,794,000 |
| Gross PPE | $81,285,000 | $83,704,000 | $90,462,000 | $74,940,000 |
| Leases | $4,343,000 | $4,095,000 | $3,763,000 | $3,350,000 |
| Other Properties | $32,209,000 | $32,207,000 | $42,496,000 | $33,524,000 |
| Machinery Furniture Equipment | $44,733,000 | $47,402,000 | $44,203,000 | $38,066,000 |
| Properties | $0 | $0 | $0 | $0 |
| Finished Goods | $60,996,000 | $70,377,000 | $70,271,000 | $66,312,000 |
| Raw Materials | $21,240,000 | $22,098,000 | $21,062,000 | $18,454,000 |
| Treasury Shares Number | - | - | $0 | $0 |
| Investments And Advances | - | - | - | $2,636,000 |
| Inventories Adjustments Allowances | - | - | - | $-1,851,000 |
Fetched: 2026-06-17
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $72,111,000 | $37,789,000 | $7,982,000 | $-15,015,000 |
| Operating Activities | ||||
| Operating Cash Flow | $74,673,000 | $38,795,000 | $15,344,000 | $-13,537,000 |
| Cash From Discontinued Operating Activities | $0 | $0 | $-2,169,000 | $-2,130,000 |
| Cash Flow From Continuing Operating Activities | $74,673,000 | $38,795,000 | $17,513,000 | $-11,407,000 |
| Operating Gains Losses | $47,000 | $33,000 | $4,242,000 | $-5,013,000 |
| Investing Activities | ||||
| Capital Expenditure | $-2,562,000 | $-1,006,000 | $-7,362,000 | $-1,478,000 |
| Investing Cash Flow | $-3,248,000 | $22,963,000 | $15,807,000 | $-116,436,000 |
| Cash From Discontinued Investing Activities | $0 | $0 | $-11,506,000 | $-104,841,000 |
| Cash Flow From Continuing Investing Activities | $-3,248,000 | $22,963,000 | $27,313,000 | $-11,595,000 |
| Net Other Investing Changes | - | - | - | $-75,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $2,074,000 | $2,442,000 | $778,000 | $5,822,000 |
| Financing Cash Flow | $-62,140,000 | $-54,580,000 | $-26,653,000 | $62,076,000 |
| Cash Flow From Continuing Financing Activities | $-62,140,000 | $-54,580,000 | $-26,653,000 | $62,076,000 |
| Net Other Financing Charges | $-21,304,000 | $2,562,000 | $-4,167,000 | $-3,367,000 |
| Net Common Stock Issuance | $2,074,000 | $2,442,000 | $778,000 | $5,822,000 |
| Common Stock Issuance | $2,074,000 | $2,442,000 | $778,000 | $5,822,000 |
| Cash Dividends Paid | - | - | - | $0 |
| Common Stock Dividend Paid | - | - | - | $0 |
| Other | ||||
| Repayment Of Debt | $-119,817,000 | $-59,584,000 | $-87,264,000 | $-45,038,000 |
| Issuance Of Debt | $76,907,000 | $0 | $64,000,000 | $104,659,000 |
| End Cash Position | $51,238,000 | $41,582,000 | $36,964,000 | $31,837,000 |
| Beginning Cash Position | $41,582,000 | $36,964,000 | $31,837,000 | $99,213,000 |
| Effect Of Exchange Rate Changes | $371,000 | $-2,560,000 | $629,000 | $521,000 |
| Changes In Cash | $9,285,000 | $7,178,000 | $4,498,000 | $-67,897,000 |
| Net Issuance Payments Of Debt | $-42,910,000 | $-59,584,000 | $-23,264,000 | $59,621,000 |
| Net Long Term Debt Issuance | $-42,910,000 | $-59,584,000 | $-23,264,000 | $59,621,000 |
| Long Term Debt Payments | $-119,817,000 | $-59,584,000 | $-87,264,000 | $-45,038,000 |
| Long Term Debt Issuance | $76,907,000 | $0 | $64,000,000 | $104,659,000 |
| Net Investment Purchase And Sale | $0 | $-709,000 | $0 | $-10,042,000 |
| Net Business Purchase And Sale | $-686,000 | $24,678,000 | $34,675,000 | $0 |
| Purchase Of Business | $-686,000 | - | $0 | $-104,841,000 |
| Net PPE Purchase And Sale | $-2,562,000 | $-1,006,000 | $-7,362,000 | $-1,478,000 |
| Purchase Of PPE | $-2,562,000 | $-1,006,000 | $-7,362,000 | $-1,478,000 |
| Change In Working Capital | $-13,840,000 | $-11,780,000 | $-3,181,000 | $-29,730,000 |
| Change In Other Working Capital | $-1,679,000 | $-2,525,000 | $-1,970,000 | $9,659,000 |
| Change In Payables And Accrued Expense | $-19,814,000 | $17,846,000 | $-5,275,000 | $-3,099,000 |
| Change In Inventory | $8,569,000 | $-16,435,000 | $-5,991,000 | $-18,618,000 |
| Change In Receivables | $-916,000 | $-10,666,000 | $10,055,000 | $-17,672,000 |
| Changes In Account Receivables | $-916,000 | $-10,666,000 | $10,055,000 | $-17,672,000 |
| Other Non Cash Items | $1,161,000 | $4,233,000 | $2,426,000 | $1,490,000 |
| Stock Based Compensation | $12,673,000 | $13,274,000 | $2,722,000 | $17,585,000 |
| Provisionand Write Offof Assets | $1,256,000 | $-434,000 | $-1,103,000 | $5,190,000 |
| Asset Impairment Charge | $0 | $36,357,000 | $78,615,000 | $134,982,000 |
| Deferred Tax | $-909,000 | $-5,394,000 | $-2,377,000 | $-46,658,000 |
| Deferred Income Tax | $-909,000 | $-5,394,000 | $-2,377,000 | $-46,658,000 |
| Depreciation Amortization Depletion | $47,011,000 | $49,555,000 | $57,365,000 | $55,398,000 |
| Depreciation And Amortization | $47,011,000 | $49,555,000 | $57,365,000 | $55,398,000 |
| Net Foreign Currency Exchange Gain Loss | $-360,000 | $-259,000 | $665,000 | $1,383,000 |
| Net Income From Continuing Operations | $27,274,000 | $-47,049,000 | $-121,196,000 | $-144,651,000 |
| Sale Of Business | - | $24,678,000 | $34,675,000 | $0 |
| Net Intangibles Purchase And Sale | - | - | $0 | $-1,478,000 |
| Purchase Of Intangibles | - | - | $0 | $-1,478,000 |
| Pension And Employee Benefit Expense | - | - | $0 | $0 |
| Gain Loss On Investment Securities | - | - | - | $-6,396,000 |
| Net Short Term Debt Issuance | - | - | - | - |
| Short Term Debt Payments | - | - | - | - |
| Short Term Debt Issuance | - | - | - | - |
Fetched: 2026-06-17